Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines

Drug and Chemical Toxicology

Volumn 33, Issue 2, 2010, Pages 113-119

  Elahian, Fatemeh ^a,b   Kalalinia, Fatemeh ^a,b   Behravan, Javad ^a,b  

^a Bu Ali Research Institute   (Iraq)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dexamethasone; Glucocorticoids; Indomethacin; Multidrug resistance; NSAIDs

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DEXAMETHASONE; INDOMETACIN; MITOXANTRONE; NOVOBIOCIN;

ARTICLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CYTOMETRY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOMETHACIN; MITOXANTRONE; NEOPLASM PROTEINS; NOVOBIOCIN;

EID: 77949892098     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480540903390000     Document Type: Article

References (44)

1. Andrews, P., Xu, Z., Allen, J., et al. (2008). A comparison of the efectiveness of selected non-steroidal anti-infammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol 61:203-214.
2. Benyahia, B., Huguet, S., Decleves, X., et al. (2004). Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol 66:65-70.
3. Cha, Y. I., DuBois, R. N. (2007). NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58:239-252.
4. Cooray, H. C., Shahi, S., Cahn, A. P., et al. (2006). Modulation of P-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. Eur J Pharmacol 531:25-33.
5. Dmitrovsky, E. (2003). Combining cytotoxic chemotherapy with cyclooxygenase-2 inhibition. J Clin Oncol 21:2631-2632.
6. Doyle, L. A., Ross, D. D. (2003). Multidrug resistance mediated by the breast cancer resistance protein, BCRP (ABCG2). Oncogene 22:7340-7358.
7. Ee, P. L., Kamalakaran, S., Tonetti, D., et al. (2004). Identifcation of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 64:1247-1251.
8. El-Sheikh, A. A., van den Heuvel, J. J., Koenderink, J. B., et al. (2007). Interaction of nonsteroidal anti-infammatory drugs with multidrug resistance protein (MRP) 2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ter 320:229-235.
9. Fardel, O., Lecureur, V., Guillouzo, A. (1993). Regulation by dex-amethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Lett 327:189-193.
10. Flescher, E., Rotem, R., Kwon, P., et al. (2000). Aspirin enhances multidrug resistance gene 1 expression in human Molt-4 T lymphoma cells. Anticancer Res 20:4441-4444.
11. Gedeon, C., Behravan, J., Koren, G., et al. (2006). Transport of gly-buride by placental ABC transporters: implications in fetal drug exposure. Placenta 27:1096-1102.
12. Giercksky, K. E. (2001). COX-2 inhibition and prevention of cancer. Best Pract Res Clin Gastroenterol 15:821-833.
13. Gruol, D. J., Bourgeois, S. (1997). Chemosensitizing steroids: glucocorticoid receptor agonists capable of inhibiting P-glycoprotein function. Cancer Res 57:720-727.
14. Harris, R. E., Alshafe, G. A., Abou-Issa, H., et al. (2000). Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res 60:2101-2103.
15. Honggang, W., Jashvant, D. U., Qingcheng, M. (2008). Hormonal regulation of BCRP expression in human placental BeWo cells. Pharm Res 25:444-452.
16. Howe, L. R., Subbaramaiah, K., Brown, A. M., et al. (2001). Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8:97-114.
17. Kang, H. K., Lee, E., Pyo, H., et al. (2005). Cyclooxygenase-independent downregulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ter 4:1358-1363.
18. Kismet, K., Akay, M. T., Abbasoglu, O., et al. (2004). Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 28:127-142.
19. Kowalski, P., Stein, U., Schefer, G. L., et al. (2002). Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/ MXR/ABCG2. Cancer Gene Ter 9:579-586.
20. Lin, J., Hsiao, P. W., Chiu, T. H., et al. (2005). Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 70:658-667.
21. Matsunaga, S., Asano, T., Tsutsuda-Asano, A., et al. (2006). Indomethacin overcomes doxorubicin resistance with inhibiting multidrug resistance protein 1 (MRP1). Cancer Chemother Pharmacol 58:348-353.
22. Minderman, H., Suvannasaankha, A., O'Loughlin, K. L., et al. (2002). Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48:59-65.
23. Mosafa, F. , Lage, H., Tavakol Afshari, J., et al. (2009). Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Infamm Res 58:669-676.
24. Nakagawa, M., Schneider, E., Dixon, K. H. et al. (1992). Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 52:6175-6181.
25. Pavek, P., Merino, G., Wagenaar, E., et al. (2005). Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ter 312:144-152.
26. Puhlmann, U., Ziemann, C., Ruedell, G., et al. (2005). Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ter 312:346-354.
27. Raspollini, M. R., Amunni, G., Villanucci, A., et al. (2005). Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 15:255-260.
28. Ratnasinghe, D., Daschner, P. J, Anver, M. R., et al. (2001). Cyclooxygenase-2, P-glycoprotein-170, and drug resistance: is chemoprevention against multidrug resistance possible? Anticancer Res 21:2141-2147.
29. Robey, R. W., Medina-Perez, W. Y., Nishiyama, K., et al. (2001). Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in favopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145-152.
30. Roller, A., Bahr, O. R., Strefer, J., et al. (1999). Selective potentia-tion of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun 259:600-605.
31. Schinkel, A. H., Jonker, J. W. (2003). Mammalian drug efux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
32. Sorokin, A. (2004). Cyclooxygenase-2: potential role in regulation of drug efux and multidrug resistance phenotype. Curr Pharm Des 10:647-657.
33. Spugnini, E. P., Cardillo, I., Verdina, A., et al. (2006). Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res 12:6133-6143.
34. Sugimoto, Y., Tsukahara, S., Imai, Y., et al. (2003). Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ter 2:105-112.
35. Surowiak, P. , Materna, V., Matkowski, R., et al. (2005). Relationship between the expression of cyclooxygenase-2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic signifcance. Breast Cancer Res 7:R862-R870.
36. Tatebe, S., Sinicrope, F. A., Kuo, M. T. (2002). Induction of multidrug-resistance proteins MRP1 and MRP3 and gam-ma-glutamylcysteine synthetase gene expression by nonster-oidal anti-infammatory drugs in human colon cancer cells. Biochem Biophys Res Commun 290:1427-1433.
37. Van der Kolk, D. M., Vellenga, E., Schefer, G. L., et al. (2002). Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99:3763-3770.
38. Van der Pol, M. A., Pater, J. M., Feller, N., et al. (2001). Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia. Leukemia 15:1554-1563.
39. Van Wijngaarden, J., van Beek, E., van Rossum, G., et al. (2007). Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 43:433-442.
40. Verdina, A., Cardillo, I., Nebbioso, A., et al. (2008). Molecular analysis of the efects of piroxicam and cisplatin on mesothelioma cells growth and viability. J Transl Med 6:27.
41. Yaming, S. U., Sung-Hack, L., Patrick, J. S. (2006). Inhibition of efux transporter ABCG2/BCRP does not restore mitox-antrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance. Eur J Pharm Sci 29:102-110.
42. Zatelli, M. C., Luchin, A., Piccin, D.,et al. (2005). Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 90:5754-5760.
43. Zhao, J. Y., Ikeguchi, M., Eckersberg, T., et al. (1993). Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 133:521-528.
44. Zrieki, A., Farinotti, R., Buyse, M. (2008). Cyclooxygenase inhibitors downregulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res 25:1991-2001.